Education
About Us
Working with TipRanks
Follow Us
TCAL - ETF AI Analysis
Top Page
T. Rowe Price Capital Appreciation Premium Income ETF (TCAL)
Rating:72Outperform
Price Target:―
Positive Factors
Balanced Sector Mix
The fund spreads its investments across several sectors like health care, industrials, utilities, and financials, which helps reduce the impact if any one area of the market struggles.
Resilient Top Holdings
Several of the largest positions, such as Thermo Fisher, Booz Allen, and Service International, have shown strong year-to-date performance, providing support for the ETF’s overall returns.
Moderate Expense Ratio
The fund’s expense ratio is reasonable for an actively managed strategy, so investors are not paying unusually high ongoing fees for professional management.
Negative Factors
Recent Short-Term Weakness
The ETF has shown weak performance over the past one and three months, which may concern investors looking for near-term momentum.
Heavy U.S. Concentration
With almost all assets invested in U.S. companies, the fund offers little geographic diversification and is highly tied to the U.S. market’s fortunes.
Mixed Results Among Top Holdings
Some key positions, including Mastercard and several others in the top 10, have lagged year-to-date, which can drag on the fund’s overall performance.
TCAL vs. SPDR S&P 500 ETF (SPY)
AUM264.17M
RegionNorth America
Expense Ratio0.34%
Beta0.29
IssuerT. Rowe Price
Inception DateMar 26, 2025
Dividend Yield10.06%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume153,600
30 Day Avg. Volume156,425
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
26.69Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering84
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TCAL Summary
TCAL is the T. Rowe Price Capital Appreciation Premium Income ETF, an actively managed fund that invests in a wide mix of U.S. companies across many sectors instead of tracking a specific index. It focuses on the total U.S. stock market and uses a covered call strategy to try to generate extra income while aiming for growth and some stability. Well-known holdings include McDonald’s and Mastercard. Someone might consider TCAL for diversified stock exposure plus regular income. A key risk is that it still invests in stocks, so its value can go up and down with the overall market.
How much will it cost me?The T. Rowe Price Capital Appreciation Premium Income ETF (TCAL) has an expense ratio of 0.34%, meaning you’ll pay $3.40 per year for every $1,000 invested. This is higher than the average for passively managed ETFs because TCAL is actively managed, using strategies like covered call options to enhance income and manage risk.
What would affect this ETF?Positive drivers for TCAL could include stable or declining interest rates, which may support growth in sectors like health care and technology, as well as strong consumer demand benefiting defensive stocks like PepsiCo and Kroger. On the negative side, rising interest rates or economic slowdowns could pressure financial and industrial sectors, while regulatory changes in health care or real estate could impact top holdings like Thermo Fisher and SBA Communications. TCAL’s covered call strategy may help mitigate volatility in uncertain market conditions.
TCAL Top 10 Holdings
TCAL leans heavily into U.S. industrials and health care, and its leaders are doing much of the heavy lifting. Teledyne, Ametek, and GE Healthcare have been steadily rising, giving the fund a solid backbone of growth-oriented industrial and medical names. Gilead adds a healthy dose of momentum from the biotech side, while McDonald’s offers a more defensive, slow-and-steady boost. On the flip side, payment giants Visa and Mastercard have been losing steam lately, quietly tugging at returns even as the broader portfolio stays well diversified across the U.S. market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Mastercard | 2.03% | $5.40M | $464.63B | -9.38% | 75 Outperform | |
| Visa | 1.99% | $5.29M | $610.90B | -11.42% | 70 Outperform | |
| GE Healthcare Technologies Inc | 1.96% | $5.23M | $36.53B | -7.28% | 78 Outperform | |
| Thermo Fisher | 1.93% | $5.13M | $188.93B | -2.88% | 72 Outperform | |
| Waste Connections | 1.91% | $5.08M | $44.27B | -9.80% | 75 Outperform | |
| Republic Services | 1.88% | $4.99M | $71.14B | -3.86% | 72 Outperform | |
| Veralto Corporation | 1.86% | $4.94M | $24.10B | -2.65% | 76 Outperform | |
| Ametek | 1.78% | $4.73M | $55.29B | 29.43% | 79 Outperform | |
| Medtronic | 1.71% | $4.56M | $125.95B | 4.03% | 80 Outperform | |
| Gilead Sciences | 1.70% | $4.53M | $186.25B | 29.35% | 78 Outperform |
TCAL Technical Analysis
Positive
―
Price Trends
23.47
Positive
23.33
Positive
23.16
Positive
Market Momentum
0.08
Negative
61.63
Neutral
88.19
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TCAL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 23.54, equal to the 50-day MA of 23.47, and equal to the 200-day MA of 23.16, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 61.63 is Neutral, neither overbought nor oversold. The STOCH value of 88.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCAL.
TCAL Peer Comparison
Comparison Results
Performance Comparison
TCAL
T. Rowe Price Capital Appreciation Premium Income ETF
23.89
1.21
5.34%
ULTY
YieldMax Ultra Option Income Strategy ETF
―
―
―
SYLD
Cambria Shareholder Yield ETF
―
―
―
ABFL
Fcf Us Quality Etf
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
XCHG
AB US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents